Currently, research focused on re-establishing suppressed anti-tumor immunity has examined monoclonal antibody (mAb)-based interventions by targeting CTL antigen 4 (CTLA-4) [5,6] and programmed cell death protein 1 (PD-1) on T lymphocytes and its primary ligand (PD-L1) on tumor cells [7,8]. The gene discussed is CTLA4; the disease is neoplasm.